title: High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors.
abstract: OBJECTIVE
  To evaluate viability of isolated peripheral blood mononuclear cells (PBMC) and production of cytokines in vitro after stimulation as prognostic factors for survival in sepsis patients.
  
  
  METHODS
  Prospective study of the biological response of PBMC in the onset of severe sepsis.
  
  
  METHODS
  Research laboratory of molecular biology and immunology and university hospital ICU, Faculty of Medicine, Trakia University.
  
  
  METHODS
  Twenty-three patients meeting the criteria for severe sepsis, and 14 control subjects.
  
  
  METHODS
  Isolated PBMC were stimulated in vitro with: C3-binding glycoprotein (C3bgp; 30 microg), lipopolysaccharide (30 microg), phytohemagglutinin (20 microg), pokeweed mitogen (30 microg), and dexamethasone (500 microg).
  
  
  RESULTS
  We measured the levels of interleukins (IL) 6, 10, and 12 in culture supernatants. Stimulation with C3bgp and phytohemagglutinin led to significantly lower PBMC secretion of IL-6 in nonsurvivors than in survivors and healthy donors. Stimulation with C3bgp, lipopolysaccharide, and pokeweed mitogen considerably reduced IL-12 production in nonsurvivors. Stimulation with lipopolysaccharide and pokeweed mitogen caused immune cells in nonsurvivors to produce higher levels of IL-10 than in survivors. Survival of PBMC reduced viability for nonsurvivors' PBMC, both spontaneously and as induced by lipopolysaccharide or pokeweed mitogen.
  
  
  CONCLUSIONS
  The viability of PBMC at the onset of sepsis and enhanced production of IL-12 and diminished production of IL-10 after stimulation with all stimuli used may be a favorable prognostic factor in sepsis.
authors.affiliation: Department of Molecular Biology, Immunology, and Genetics, Faculty of Medicine, Thrakia University, Stara Zagora, Bulgaria. stanilova@mf.uni-sz.bg
authors.forename: Spaska A
authors.initials: SA
authors.lastname: Stanilova
authors.forename: Zhivko T
authors.initials: ZT
authors.lastname: Karakolev
authors.forename: Gospodin S
authors.initials: GS
authors.lastname: Dimov
authors.forename: Zlatka G
authors.initials: ZG
authors.lastname: Dobreva
authors.forename: Lyuba D
authors.initials: LD
authors.lastname: Miteva
authors.forename: Emil S
authors.initials: ES
authors.lastname: Slavov
authors.forename: Chavdar S
authors.initials: CS
authors.lastname: Stefanov
authors.forename: Noyko S
authors.initials: NS
authors.lastname: Stanilov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002470:Cell Survival; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D018664:Interleukin-12 / Q000096:biosynthesis*; D015850:Interleukin-6 / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012016:Reference Values; D012680:Sensitivity and Specificity; D018805:Sepsis / Q000276:immunology* / Q000378:metabolism*; D016019:Survival Analysis
chemical_list: D016207:Cytokines; D015850:Interleukin-6; D016753:Interleukin-10; D018664:Interleukin-12
references.citation: J Immunol. 1994 May 15;152(10):5014-21
references.pmid: 8176219
references.citation: Arch Surg. 1994 Feb;129(2):187-92
references.pmid: 8304829
references.citation: Shock. 2000 Mar;13(3):169-74
references.pmid: 10718372
references.citation: Immunol Lett. 2004 Sep;95(2):193-8
references.pmid: 15388260
references.citation: Infection. 1997 Jul-Aug;25(4):206-12
references.pmid: 9266258
references.citation: Arch Immunol Ther Exp (Warsz). 1997;45(4):277-84
references.pmid: 9523001
references.citation: Surgery. 2000 Mar;127(3):309-15
references.pmid: 10715987
references.citation: J Trauma. 1995 Jul;39(1):104-10; discussion 110-1
references.pmid: 7636900
references.citation: FASEB J. 2001 Apr;15(6):879-92
references.pmid: 11292647
references.citation: Ann Surg. 2000 Feb;231(2):253-61
references.pmid: 10674618
references.citation: Shock. 2002 Dec;18(6):487-94
references.pmid: 12462554
references.citation: Ann Surg. 2002 Apr;235(4):560-7
references.pmid: 11923613
references.citation: Int Immunopharmacol. 2001 Aug;1(8):1597-604
references.pmid: 11515822
references.citation: Infect Immun. 2001 Apr;69(4):2099-106
references.pmid: 11254563
references.citation: Crit Care Med. 2002 Sep;30(9):1987-94
references.pmid: 12352031
references.citation: Blood. 1995 Mar 1;85(5):1341-7
references.pmid: 7858264
references.citation: Int J Immunopharmacol. 2000 Jan;22(1):15-24
references.pmid: 10684985
references.citation: J Lab Clin Med. 1996 Dec;128(6):594-600
references.pmid: 8960643
references.citation: Crit Care Med. 1997 Aug;25(8):1298-307
references.pmid: 9267941
references.citation: Nat Cell Biol. 2002 Jan;4(1):26-31
references.pmid: 11780128
references.citation: Crit Care Med. 2000 Jul;28(7):2591-4
references.pmid: 10921600
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Ann Surg. 1996 Apr;223(4):434-40
references.pmid: 8633923
references.citation: N Engl J Med. 2003 Jan 9;348(2):138-50
references.pmid: 12519925
references.citation: J Immunol. 1997 May 1;158(9):4422-9
references.pmid: 9127007
references.citation: Crit Care Med. 1992 Jun;20(6):864-74
references.pmid: 1597042
references.citation: Intensive Care Med. 1996 Jul;22(7):707-10
references.pmid: 8844239
references.citation: Crit Care Med. 2004 May;32(5 Suppl):S202-8
references.pmid: 15118518
references.citation: Br J Dermatol. 1996 Feb;134(2):199-207
references.pmid: 8746330
references.citation: J Infect Dis. 2000 Jan;181(1):176-80
references.pmid: 10608764
references.citation: Biochem Biophys Res Commun. 1994 Jul 15;202(1):186-94
references.pmid: 8037713
references.citation: Intensive Care Med. 2004 Jun;30(6):1017-31
references.pmid: 15170528